Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

32.28 +1.28 (+4.13%)

Streaming Delayed Price Updated: 9:39 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story ↗

December 27, 2025

Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story

Via The Motley Fool

Topics Regulatory Compliance

Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 ↗

December 24, 2025

Duquesne Family Office's billionaire boss has jettisoned the faces of the artificial intelligence (AI) revolution in favor of a drugmaker whose shares have rallied 191% since the beginning of 2024.

Via The Motley Fool

Topics Artificial Intelligence

My Top 10 Portfolio Holdings for 2026 ↗

December 19, 2025

This combination of growth and value stocks has the tools and intangibles necessary to outperform in the year to come.

Via The Motley Fool

Topics Stocks

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today ↗

December 17, 2025

Teva Pharmaceutical is more complex than you may realize, even though that's part of the company's plan.

Via The Motley Fool

Topics Intellectual Property

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? ↗

December 14, 2025

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

Via The Motley Fool

Topics Intellectual Property

Glenview Capital Management Sells $71 Million of Alight Stake After Stock's 71% Drop ↗

December 09, 2025

Glenview Capital Management reduced its stake in Alight by roughly 16% during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing ↗

December 09, 2025

Glenview Capital Management added to its massive position in Teva Pharmaceuticals stock.

Via The Motley Fool

Topics Regulatory Compliance

Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035

December 03, 2025

The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,...

Via MarketMinute

Topics Artificial Intelligence Death Intellectual Property

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks ↗

November 30, 2025

Stanley Druckenmiller is considered one of the greatest investors of all time.

Via The Motley Fool

Topics Artificial Intelligence

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗

November 27, 2025

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Via Stocktwits

Topics ETFs

JPMorgan Says 2027 Medicare Drug Prices Signal Up To 40% Cuts Ahead — Novo Nordisk And Teva Stand Out As Top Targets ↗

November 26, 2025

JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.

Via Stocktwits

Topics Economy Government

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Via Investor's Business Daily

Topics Economy Government

Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report ↗

November 19, 2025

Jury convicts Done Global founder Ruthia He and former top doctor David Brody in a federal case alleging illegal Adderall distribution through the telehealth platform.

Via Benzinga

Topics Law Enforcement

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 11, 2025

Via Benzinga

Billionaire Stanley Druckenmiller Sold His Fund's Entire Stakes in Nvidia and Palantir for a Scorching-Hot Drug Stock That's Up 218% Since Mid-2023 ↗

November 11, 2025

Duquesne Family Office's billionaire boss has gone full contrarian by selling Wall Street's two artificial intelligence (AI) darlings and piling into a previously struggling pharmaceutical stock.

Via The Motley Fool

Topics Artificial Intelligence

Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today ↗

November 10, 2025

Via Benzinga

Price Over Earnings Overview: Teva Pharmaceutical Indus ↗

November 10, 2025

Via Benzinga

Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio? ↗

November 09, 2025

Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps.

Via Benzinga

Why Teva Pharmaceutical Stock Rocked the Market Today ↗

November 05, 2025

The company delivered a convincing pair of beats in its third-quarter earnings report.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗

November 05, 2025

Via Benzinga

Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook ↗

November 05, 2025

Teva Q3 revenue rose to $4.48 billion, beating estimates, as Austedo and Ajovy boosted growth; 2025 EPS outlook now $2.55–$2.65.

Via Benzinga

Market Movers: Eli Lilly, Cadre, BP, Kellanova, and Teva Soar to 52-Week Highs Amidst Shifting Economic Tides

November 05, 2025

In a period marked by cautious optimism and strategic pivots, several prominent companies across diverse sectors have recently defied broader economic uncertainties to achieve significant 52-week...

Via MarketMinute

Topics Economy Intellectual Property Supply Chain

Teva Pharma Surges On Its Big Sales Beat, Austedo Guidance Hike ↗

November 05, 2025

Teva stock jumped Wednesday on better-than-expected quarterly metrics.

Via Investor's Business Daily

Topics Earnings

Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock ↗

November 03, 2025

Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva Stock

Via The Motley Fool

Topics ETFs Economy Regulatory Compliance

Israel’s Phoenix Financial Exits $169 Million Tower Semiconductor Stake After Stock's 99% Rally ↗

November 03, 2025

Israel’s Phoenix Financial Exits $169 Million Tower Semiconductor Stake After Stock's 99% Rally

Via The Motley Fool

Topics Artificial Intelligence

Harel Bets Big on Teva Pharmaceutical by Purchasing 4.3 Million Shares ↗

October 29, 2025

Harel Bets Big on Teva Pharmaceutical by Purchasing 4.3 Million Shares

Via The Motley Fool

SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures ↗

October 15, 2025

SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.